Results of experiments showed that when the CD34+/CD38− CML LSCs have been incubated with nilotinib, they were induced to increase their spontaneous apoptosis ability. The gene discussed is CD38; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.